Overview

A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab

Status:
Recruiting
Trial end date:
2022-01-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of nemolizumab (CD14152) on humoral immune responses to tetanus and meningococcal vaccination in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).
Phase:
Phase 2
Details
Lead Sponsor:
Galderma R&D